Innovative Digital Therapeutic for Smoking Cessation
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03694327 |
Recruitment Status :
Completed
First Posted : October 3, 2018
Results First Posted : June 6, 2022
Last Update Posted : June 6, 2022
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Smoking Cessation Nicotine Addiction Drug Addiction Drug Dependence Tobacco Dependence Tobacco Use Disorder Substance Use Disorder Tobacco Smoking | Device: CT-101-M Device: QuitGuide | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 158 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double (Participant, Investigator) |
Primary Purpose: | Treatment |
Official Title: | Clinical Trial of an Innovative Digital Therapeutic for Smoking Cessation With Biochemical Verification |
Actual Study Start Date : | October 24, 2018 |
Actual Primary Completion Date : | March 14, 2019 |
Actual Study Completion Date : | March 14, 2019 |

Arm | Intervention/treatment |
---|---|
Experimental: Treatment A Mobile Application
Treatment A Digital Intervention: Smartphone application designed to assist with smoking cessation.
|
Device: CT-101-M
Mobile Application |
Active Comparator: Treatment B Mobile Application
Treatment B Digital Intervention: Smartphone application designed to assist with smoking cessation.
|
Device: QuitGuide
Mobile Application |
- 30-Day Sustained Abstinence From Smoking [ Time Frame: Upon completion of 8-week period ]Self-reported abstinence from smoking was assessed in the 8-Week Outcome Survey.
- Feasibility of Biochemical Verification of Smoking Cessation [ Time Frame: Upon completion of 8-week period ]Confirmation with the remote CO assessment was conducted to assess concordance between self-report and remote CO assessment results. Abstinence as per the CO assessment was defined as an iCO reading of fewer than 7ppm exhaled CO.
- NRT and Smoking Cessation Pharmacotherapy Use [ Time Frame: Upon completion of 8-week period ]Self-reported NRT and smoking cessation pharmacotherapy use will be acquired via the outcome survey. Cessation rates will be compared between those using/not using pharmacotherapy.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 65 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Male or female age 18 to 65
- Fluent in written and spoken English (confirmed by ability to read and comprehend Informed Consent Form)
- Lives in the United States
- Smokes at least 5 cigarettes daily
- Is interested in quitting in the next 30 days
- The participant owns and has access to an iPhone with iOS 9 or greater capabilities, or an Android with OS 7 or greater capabilities
- The participant is willing and able to receive SMS text messages on their smartphone
- The participant is willing and able to receive email messages.
- Ability to confirm download of installed treatment arm app via telephone on randomization date.
- One half of the study sample will be recruited from the general population of smokers via social media advertisements
- One half of the study sample will be recruited via mail form a Magellan Behavioral Health value-based care network
Exclusion Criteria:
- Prior use of Treatment A Digital Intervention or Treatment B Digital Intervention
- Current use of pharmacotherapy for smoking cessation or nicotine replacement therapy (NRT)

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03694327
United States, New York | |
My Digital Study | |
New York, New York, United States, 10013 |
Principal Investigator: | Brian M Iacoviello, PhD | My Digital Study |
Documents provided by My Digital Study:
Responsible Party: | My Digital Study |
ClinicalTrials.gov Identifier: | NCT03694327 |
Other Study ID Numbers: |
CT-101-002 |
First Posted: | October 3, 2018 Key Record Dates |
Results First Posted: | June 6, 2022 |
Last Update Posted: | June 6, 2022 |
Last Verified: | May 2022 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | Yes |
Device Product Not Approved or Cleared by U.S. FDA: | Yes |
Disease Substance-Related Disorders Tobacco Use Disorder Behavior, Addictive Pathologic Processes |
Compulsive Behavior Impulsive Behavior Chemically-Induced Disorders Mental Disorders |